{
    "id": 5409,
    "name": "lung small cell carcinoma",
    "source": "DOID",
    "definition": "A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung. [url:http\\://en.wikipedia.org/wiki/Small-cell_carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "0050875"
    ],
    "termId": "DOID:5409",
    "evidence": [
        {
            "id": 1251,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237), alone and in combination with Taxol (paclitaxel), inhibited growth of small cell lung cancer cell (SCLC) lines in culture and inhibited tumor growth in primary human SCLC xenograft models (Mol Cancer Ther 2013;12(11 Suppl):A282).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 558,
                    "pubMedId": null,
                    "title": "Antitumor activity of alisertib (MLN8237), an investigational small molecule Aurora A kinase inhibitor, as a single agent and in combination with paclitaxel, in experimental models of small cell lung cancer",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/A282"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7730,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Alisertib (MLN8237) resulted in an objective response in 21% (10/48) of patients with small cell lung cancer (PMID: 25728526).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3327,
                    "pubMedId": 25728526,
                    "title": "Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728526"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1252,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237), alone and in combination with Taxol (paclitaxel), inhibited growth of small cell lung cancer cell (SCLC) lines in culture and inhibited tumor growth in primary human SCLC xenograft models (Mol Cancer Ther 2013;12(11 Suppl):A282).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1679,
                "therapyName": "Alisertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 558,
                    "pubMedId": null,
                    "title": "Antitumor activity of alisertib (MLN8237), an investigational small molecule Aurora A kinase inhibitor, as a single agent and in combination with paclitaxel, in experimental models of small cell lung cancer",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/A282"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1501,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, siRNA inhibition of ID3 expression in small cell lung cancer cells decreased proliferation and resulted in decreased tumor size in xenograft models (PMID: 20664928), suggesting a role for Id3 as a potential therapeutic target.",
            "molecularProfile": {
                "id": 2613,
                "profileName": "ID3 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1426,
                    "pubMedId": 20664928,
                    "title": "Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664928"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1986,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 induced apoptosis in small-cell lung cancer (SCLC) cell lines and decreased tumor growth in SCLC cell line xenograft models harboring Tp53 inactivating mutations (PMID: 21415220).",
            "molecularProfile": {
                "id": 489,
                "profileName": "TP53 inact mut"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2429,
                    "pubMedId": 21415220,
                    "title": "PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21415220"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1155463 induced apoptosis in a BCL2L1 (BCL-XL)-dependent small cell lung cancer cell line in culture (PMID: 25787766).",
            "molecularProfile": {
                "id": 1027,
                "profileName": "BCL2L1 wild-type"
            },
            "therapy": {
                "id": 2576,
                "therapyName": "A-1155463",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2473,
                    "pubMedId": 25787766,
                    "title": "Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25787766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2086,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer cell lines with BCL2 amplification demonstrated sensitivity to Venclexta (venetoclax) in culture (PMID: 25787766).",
            "molecularProfile": {
                "id": 5016,
                "profileName": "BCL2 amp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2473,
                    "pubMedId": 25787766,
                    "title": "Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25787766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2224,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer cell lines with PARP1 overexpression demonstrated enhanced sensitivity to Camptosar (irinotecan) when treatment was combined with Lynparza (olaparib) (J Clin Oncol 30, 2012 (suppl; abstr 7096)).",
            "molecularProfile": {
                "id": 6305,
                "profileName": "PARP1 over exp"
            },
            "therapy": {
                "id": 2723,
                "therapyName": "Irinotecan + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2789,
                    "pubMedId": null,
                    "title": "Investigation of PARP1 as a therapeutic target in small cell lung cancer",
                    "url": "http://meetinglibrary.asco.org/content/98896-114"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",
            "molecularProfile": {
                "id": 686,
                "profileName": "RET wild-type"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2987,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2988,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).",
            "molecularProfile": {
                "id": 3055,
                "profileName": "RET M918T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2989,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",
            "molecularProfile": {
                "id": 686,
                "profileName": "RET wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2990,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).",
            "molecularProfile": {
                "id": 3055,
                "profileName": "RET M918T"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of MYCL correlated with sensitivity to PF-03814735 in small cell lung cancer cells in culture (PMID: 22222631).",
            "molecularProfile": {
                "id": 1428,
                "profileName": "MYCL amp"
            },
            "therapy": {
                "id": 863,
                "therapyName": "PF-03814735",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4184,
                    "pubMedId": 22222631,
                    "title": "An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22222631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3950,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-ADW742, when combined with Toposaur (etoposide), demonstrated a synergistic effect in small cell lung cancer cell lines, resulting in inhibition of Akt signaling (PMID: 15746061).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3403,
                "therapyName": "Etoposide + NVP-ADW742",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4307,
                    "pubMedId": 15746061,
                    "title": "The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15746061"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4388,
                    "pubMedId": 25169980,
                    "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25169980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of small lung cancer cells harboring TP53 Y163C in culture (PMID: 26086967).",
            "molecularProfile": {
                "id": 5742,
                "profileName": "TP53 Y163C"
            },
            "therapy": {
                "id": 3443,
                "therapyName": "APR-246 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4407,
                    "pubMedId": 26086967,
                    "title": "APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26086967"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19924,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRINITY), Rovalpituzumab Tesirine treatment resulted in moderate antitumor activity in patients with small cell lung cancer overexpressing DLL3, including an objective response rate of 14.3% (34/238) and a median overall survival of 5.7 months (PMID: 31506387; NCT02674568).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17586,
                    "pubMedId": 31506387,
                    "title": "Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31506387"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6741,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rovalpituzumab Tesirine treatment resulted in complete response or partial response in 55% (12/22) and clinical benefit in 91% (20/22) of DLL3 positive lung small cell carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr LBA8505)).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5803,
                    "pubMedId": null,
                    "title": "Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_162941.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4562,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rovalpituzumab Tesirine treatment resulted in sustained tumor regression in PDX models of small cell lung carcinoma with elevated levels of Dll3 protein (PMID: 26311731).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4615,
                    "pubMedId": 26311731,
                    "title": "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5094,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 1417,
                "profileName": "PDGFRA amp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5561,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Sutent (sunitinib) treatment in small cell lung cancer patients resulted in a partial response of 11% (1/9) and stable disease in 30% (3/9) (PMID: 26716400).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5107,
                    "pubMedId": 26716400,
                    "title": "Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26716400"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5612,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYC-amplified lung small cell carcinoma cell lines in culture and suppressed tumor growth in MYC-amplified human small cell lung cancer cell line xenograft models (PMID: 25490451).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5126,
                    "pubMedId": 25490451,
                    "title": "Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25490451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6268,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 3074,
                "therapyName": "Trilaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5519,
                    "pubMedId": 26826116,
                    "title": "Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826116"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6269,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 4109,
                "therapyName": "Topotecan + Trilaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5519,
                    "pubMedId": 26826116,
                    "title": "Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826116"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6740,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rovalpituzumab Tesirine treatment in Dll3 positive lung small cell carcinoma patients resulted in an objective response in 18% (11/60) of patients, including ten patients with overexpression of Dll3, and stable disease in 35 patients (PMID: 27932068; NCT01901653).",
            "molecularProfile": {
                "id": 19630,
                "profileName": "DLL3 positive"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5803,
                    "pubMedId": null,
                    "title": "Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_162941.html"
                },
                {
                    "id": 10548,
                    "pubMedId": 27932068,
                    "title": "Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27932068"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6866,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5821,
                    "pubMedId": 23082000,
                    "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23082000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7301,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263) and GDC-0941 resulted in increased tumor growth delay and apoptosis in a small cell lung cancer cell line xenograft model harboring a PIK3CA activating mutation compared to either drug alone (PMID: 27197306).",
            "molecularProfile": {
                "id": 743,
                "profileName": "PIK3CA act mut"
            },
            "therapy": {
                "id": 4446,
                "therapyName": "Navitoclax + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6304,
                    "pubMedId": 27197306,
                    "title": "Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27197306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7302,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263) and GDC-0941 delayed tumor growth in a circulating tumor cell (CTC)-derived xenograft model derived using CTCs from a small cell lung cancer patient (PMID: 27197306).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4446,
                "therapyName": "Navitoclax + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6304,
                    "pubMedId": 27197306,
                    "title": "Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27197306"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7778,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Adriamycin (doxorubicin) plus SLCB050 at low doses in a lung small cell carcinoma cell line xenograft model resulted in decreased tumor volume (PMID: 27302160).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4577,
                "therapyName": "Doxorubicin + SLCB050",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6487,
                    "pubMedId": 27302160,
                    "title": "Inhibiting DX2-p14/ARF Interaction Exerts Antitumor Effects in Lung Cancer and Delays Tumor Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27302160"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8050,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BDA-366 inhibited tumor growth in a patient-derived xenograft (PDX) model of small cell lung cancer (PMID: 26004684).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3275,
                "therapyName": "BDA-366",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4086,
                    "pubMedId": 26004684,
                    "title": "Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26004684"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BDA-366 decreased viability BCL2-expressing small cell lung cancer cell lines in culture, with cell lines expressing higher levels of BCL2 demonstrating increased sensitivity (PMID: 26004684).",
            "molecularProfile": {
                "id": 26142,
                "profileName": "BCL2 positive"
            },
            "therapy": {
                "id": 3275,
                "therapyName": "BDA-366",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4086,
                    "pubMedId": 26004684,
                    "title": "Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26004684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8283,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 demonstrated efficacy in xenograft models of small cell lung cancer harboring TP53 S241F (PMID: 21415220).",
            "molecularProfile": {
                "id": 16831,
                "profileName": "TP53 S241F"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2429,
                    "pubMedId": 21415220,
                    "title": "PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21415220"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8284,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 demonstrated efficacy in cell line xenograft models of small cell lung cancer harboring TP53 R273L (PMID: 21415220).",
            "molecularProfile": {
                "id": 3604,
                "profileName": "TP53 R273L"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2429,
                    "pubMedId": 21415220,
                    "title": "PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21415220"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8449,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8467,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8481,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 100% (6/6) of small cell lung cancer cell lines harboring MYC amplification demonstrated either strong or intermediate sensitivity to Barasertib (AZD1152) in culture (PMID: 27496133).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6752,
                    "pubMedId": 27496133,
                    "title": "Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung carcinoma xenograft models over expressing MYC demonstrated sensitivity to treatment with Barasertib (AZD1152), resulting in tumor growth inhibition (PMID: 27496133).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6752,
                    "pubMedId": 27496133,
                    "title": "Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8798,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) did not inhibit viability of ABL2 amplified lung small cell carcinoma cells in culture (PMID: 26758680).",
            "molecularProfile": {
                "id": 13315,
                "profileName": "ABL2 amp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8864,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer cell line xenograft and patient derived xenograft (PDX) models demonstrated stabilization of tumor growth and eventual tumor regression when treated with STA-8666 (PMID: 27267850).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4842,
                "therapyName": "STA-8666",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6776,
                    "pubMedId": 27267850,
                    "title": "A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27267850"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8865,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung carcinoma cell line xenograft models treated with Ganetespib demonstrated partial tumor growth inhibition, but with tumor progression, weight loss ensued (PMID: 27267850).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6776,
                    "pubMedId": 27267850,
                    "title": "A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27267850"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8866,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, STA-8666 enhanced antitumor activity when combined with Paraplatin (carboplatin), resulting in stabilization of tumor growth and eventual tumor regression in small cell lung cancer cell line xenograft models (PMID: 27267850).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4843,
                "therapyName": "Carboplatin + STA-8666",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6776,
                    "pubMedId": 27267850,
                    "title": "A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27267850"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9121,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).",
            "molecularProfile": {
                "id": 1276,
                "profileName": "FGFR1 rearrange"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6925,
                    "pubMedId": 27550940,
                    "title": "Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 4911,
                "therapyName": "E7090",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6928,
                    "pubMedId": 27535969,
                    "title": "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535969"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237) inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ilorasertib (ABT-348) inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 975,
                "therapyName": "ABT-348",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYC116 inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 711,
                "therapyName": "CYC116",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-901 inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1564,
                "therapyName": "TAK-901",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Alisertib (MLN8237) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alisertib (MLN8237) and Vepesid (etoposide) resulted in reduced cell viability in small cell lung cancer cell lines in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5253,
                "therapyName": "Alisertib + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alisertib (MLN8237) enhanced the sensitivity of Platinol (cisplatin) combined with Vepesid (etoposide) in small cell lung cancer mouse models expressing MYC T58A and loss of TP53 and RB1, resulting in complete tumor growth inhibition, stable disease in 62.5% (10/16), and decreased tumor volume by 30% in three of the mice (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 5257,
                "therapyName": "Alisertib + Cisplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Barasertib (AZD1152) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9864,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the addition of Avastin (bevacizumab) to treatment with Platinol (cisplatin) and Vepesid (etoposide) resulted in a median progression-free survival of 6.7 months, compared to 5.7 months with Platinol (cisplatin) and Vepesid (etoposide) in combination, but did not result in significantly improved overall survival in patients with small-cell lung cancer (PMID: 28135143).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5273,
                "therapyName": "Bevacizumab + Cisplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7719,
                    "pubMedId": 28135143,
                    "title": "Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135143"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10437,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",
            "molecularProfile": {
                "id": 27462,
                "profileName": "ALK rearrange RB1 C706F TP53 loss"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8449,
                    "pubMedId": 28285684,
                    "title": "Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28285684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10438,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Caprelsa (vandetanib) to platinum (cisplatin or carboplatin) and etoposide did not improve time to progression (5.62 vs 5.68 months) or overall survival (12.24 vs 9.23 months) compared to placebo in untreated extensive-stage small cell lung cancer (PMID: 27583688).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8450,
                    "pubMedId": 27583688,
                    "title": "A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27583688"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10748,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ12489875-002 inhibited growth of lung small cell carcinoma cells in a dose-dependent manner in culture (PMID: 23844053).",
            "molecularProfile": {
                "id": 27742,
                "profileName": "EPHB4 positive"
            },
            "therapy": {
                "id": 3418,
                "therapyName": "AZ12489875-002",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4341,
                    "pubMedId": 23844053,
                    "title": "The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23844053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10750,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sEphB4-HSA treatment induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of Ephb4-positive lung small cell carcinoma (PMID: 23844053).",
            "molecularProfile": {
                "id": 27742,
                "profileName": "EPHB4 positive"
            },
            "therapy": {
                "id": 3013,
                "therapyName": "sEphB4-HSA",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4341,
                    "pubMedId": 23844053,
                    "title": "The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23844053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10751,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock-down of Ephb4 expression via siRNA sensitized lung small cell carcinoma cell lines to SN-38 induced growth inhibition in culture (PMID: 23844053).",
            "molecularProfile": {
                "id": 27743,
                "profileName": "EPHB4 dec exp"
            },
            "therapy": {
                "id": 3982,
                "therapyName": "SN-38",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4341,
                    "pubMedId": 23844053,
                    "title": "The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23844053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11196,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment in patients with lung small cell carcinoma resulted in an objective response rate of 9% (2/23), including two patients with a partial response, and four patients with stable disease for at least 16 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a small cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 5898,
                "therapyName": "AZD4547 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9154,
                    "pubMedId": 28108151,
                    "title": "A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28108151"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11299,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYD-2-11 induced apoptosis in Bax-expressing small cell lung cancer (SCLC) cell lines in culture, with cell lines with higher total and phosphorylated Bax expression demonstrating increased sensitivity, and induced apoptosis and inhibited tumor growth in SCLC cell line xenograft and patient-derived xenograft (PDX) models (PMID: 28381544).",
            "molecularProfile": {
                "id": 27944,
                "profileName": "BAX positive"
            },
            "therapy": {
                "id": 5927,
                "therapyName": "CYD-2-11",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9215,
                    "pubMedId": 28381544,
                    "title": "Modulation of Bax and mTOR for Cancer Therapeutics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28381544"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11477,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified lung small cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 2899,
                "therapyName": "GSK3052230",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9409,
                    "pubMedId": 23536011,
                    "title": "Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23536011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11479,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 6002,
                "therapyName": "Cisplatin + Etoposide + GSK3052230",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9409,
                    "pubMedId": 23536011,
                    "title": "Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23536011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16261,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in superior objective response rate (35.7%, 15/24 vs 6.0%, 3/50), median progression-free survival (2.1 vs 1.9 months), and median overall survival (14.6 vs 7.7 months) in patients with CD274 (PD-L1)-positive (combined positive score>=1) advanced small cell lung cancer compared to patients with CD274 (PD-L1)-negative tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 8506-8506; NCT02628067).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14400,
                    "pubMedId": null,
                    "title": "Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8506"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11861,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 33% (8/24) in patients with lung small cell carcinoma expressing CD274 (PD-L1)in 1% or more of tumor or stromal cells by IHC, including one patient with a complete response and seven patients with a partial response (PMID: 28813164; NCT02054806).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9876,
                    "pubMedId": 28813164,
                    "title": "Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28813164"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12125,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with Sacituzumab Govitecan resulted in an objective response rate of 14% (7/50), which included 7 patients achieving a partial response, and a median response duration of 5.7 months in patients with lung small cell carcinoma (PMID: 28679770).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3227,
                "therapyName": "Sacituzumab govitecan",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10100,
                    "pubMedId": 28679770,
                    "title": "Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679770"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12187,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lurbinectedin (PM01183) and Adriamycin (doxorubicin) combination treatment resulted in complete response in 8% (2/27) and partial response in 50% (13/27) of patients with relapsed small-cell lung cancer (PMID: 28961837).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6311,
                "therapyName": "Doxorubicin + Lurbinectedin",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10142,
                    "pubMedId": 28961837,
                    "title": "Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961837"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12241,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression and activation of Met was identified in a small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12242,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 and Xalkori (crizotinib) synergistically inhibited Erk signaling, resulted in growth inhibition in small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 6374,
                "therapyName": "BGJ398 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12243,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 and EMD 1214063 synergistically inhibited growth of small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 6372,
                "therapyName": "BGJ398 + EMD 1214063",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12318,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Navitoclax (ABT-263) in 39 patients with lung small cell carcinoma resulted in a partial response in 1 patient and stable disease in 9 patients, and led to increased apoptotic activity and decreased circulating tumor cell levels in patients with BCL2 amplification (PMID: 22496272).",
            "molecularProfile": {
                "id": 5016,
                "profileName": "BCL2 amp"
            },
            "therapy": {
                "id": 825,
                "therapyName": "Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10292,
                    "pubMedId": 22496272,
                    "title": "Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22496272"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12328,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, T-3775440 treatment led to decreased cell proliferation in lung small cell carcinoma cell lines in culture, demonstrating reduced expression of INSM1 or GFI1B, and inhibited tumor growth in lung small cell carcinoma cell line xenograft models (PMID: 28667074).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5293,
                "therapyName": "T-3775440",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10329,
                    "pubMedId": 28667074,
                    "title": "LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28667074"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12743,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer cell lines, which expressed high levels of CHEK1, demonstrated sensitivity to PF-00477736 treatment, resulting in decreased viability in culture and reduced tumor growth in xenograft models (PMID: 29138515).",
            "molecularProfile": {
                "id": 28910,
                "profileName": "CHEK1 over exp"
            },
            "therapy": {
                "id": 1565,
                "therapyName": "PF-00477736",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10681,
                    "pubMedId": 29138515,
                    "title": "Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29138515"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12744,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer cell lines, which expressed high levels of CHEK1, demonstrated sensitivity to VX-970 treatment, resulting in decreased viability in culture and reduced tumor growth in xenograft models (PMID: 29138515).",
            "molecularProfile": {
                "id": 28910,
                "profileName": "CHEK1 over exp"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10681,
                    "pubMedId": 29138515,
                    "title": "Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29138515"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13984,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial (CheckMate 032), Opdivo (nivolumab) treatment resulted in higher objective response rate in small cell lung carcinoma patients with high (21.3%, 10/47) tumor mutational burden (TMB) compared to patients with low (4.8%, 2/42) or medium (6.8%, 3/44) TMB, higher estimated 1-year progression-free survival rate (21.2%, not calculable, 3.1%, respectively), and higher estimated 1-year overall survival rate (35.2%, 22.1%, 26.0%, respectively) (PMID: 29731394; NCT01928394).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11400,
                    "pubMedId": 29731394,
                    "title": "Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29731394"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16652,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, immune-checkpoint inhibitors (Keytruda (pembrolizumab), n=7; Opdivo (nivolumab), n=24; Opdivo (nivolumab) plus Yervoy (ipilimumab), n=21) resulted in significantly improved median progression-free survival (3.3 vs 1.2 mo, HR=0.37, p<0.01) and median overall survival (10.4 vs 2.5 mo, HR=0.38, p<0.01) in small cell lung cancer patients with high tumor mutational burden (TMB>9.68mut/MB) compared to patients with low TMB (TMB less or equal to 9.68mut/MB) (PMID: 30922388).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14702,
                    "pubMedId": 30922388,
                    "title": "Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30922388"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13985,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial (CheckMate 032), Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy resulted in higher objective response rate in small cell lung cancer patients with high (46.2%, 12/26) tumor mutational burden (TMB) compared to patients with low (22.2%, 6/27) or medium (16.0%, 4/25) TMB, higher estimated 1-year progression-free survival rate (30.0%, 6.2%, 8.0%), and higher estimated 1-year overall survival rate (62.4%, 23.4%, 19.6%) (PMID: 29731394; NCT01928394).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11400,
                    "pubMedId": 29731394,
                    "title": "Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29731394"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16653,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, immune-checkpoint inhibitors (Keytruda (pembrolizumab), n=7; Opdivo (nivolumab), n=24; Opdivo (nivolumab) plus Yervoy (ipilimumab), n=21) resulted in significantly improved median progression-free survival (3.3 vs 1.2 mo, HR=0.37, p<0.01) and median overall survival (10.4 vs 2.5 mo, HR=0.38, p<0.01) in small cell lung cancer patients with high tumor mutational burden (TMB>9.68mut/MB) compared to patients with low TMB (TMB less or equal to 9.68mut/MB) (PMID: 30922388).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14702,
                    "pubMedId": 30922388,
                    "title": "Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30922388"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16515,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Opdivo (nivolumab) is included in guidelines for small cell lung cancer patients who have relapsed after primary therapy (NCCN.org).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14985,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial (CheckMate 032) that supported FDA approval, Opdivo (nivolumab) as third- or later-line treatment resulted in an objective response rate of 11.9% (13/109, 1 complete response, 12 partial response) in patients with metastatic small cell lung cancer, with a median duration of response of 17.9 months (PMID: 29731394, PMID: 30316010; NCT01928394).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11400,
                    "pubMedId": 29731394,
                    "title": "Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29731394"
                },
                {
                    "id": 14516,
                    "pubMedId": 30316010,
                    "title": "Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30316010"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15207,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Roniciclib (BAY 1000394) at the RP2D reduced PCNA expression and resulted in a disease control rate of 17.4% (n=23) in patients with small cell lung cancer (PMID: 28463960; NCT01188252).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 663,
                "therapyName": "Roniciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12811,
                    "pubMedId": 28463960,
                    "title": "Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463960"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15211,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, first-line treatment with the combination of Roniciclib (BAY1000394) and either carboplatin plus etoposide or cisplatin plus etoposide demonstrated tolerability and resulted in a response rate of 81.4% (35/43; all partial responses), median OS of 12.6 mo, and median PFS of 7.3 mo in extensive disease small cell lung cancer patients; however due to a safety signal in a related trial further development of Roniciclib (BAY1000394) was discontinued (PMID: 30089585; NCT01573338).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7467,
                "therapyName": "Carboplatin + Etoposide + Roniciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12841,
                    "pubMedId": 30089585,
                    "title": "Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30089585"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15223,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small-cell lung carcinoma cell lines with overexpression of Trib2 were resistant to cisplatin (PMID: 29312632).",
            "molecularProfile": {
                "id": 24498,
                "profileName": "TRIB2 over exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12871,
                    "pubMedId": 29312632,
                    "title": "TRIB2 contributes to cisplatin resistance in small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29312632"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15357,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talzenna (talazoparib) treatment resulted in reduced tumor growth in small cell lung carcinoma cell line xenograft models with overexpression of SLFN11 and high MGMT, however, to a lesser extent than when compared to the combination of Talzenna (talazoparib) and Temodar (temozolomide) (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15358,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Talzenna (talazoparib) and Temodar (temozolomide) resulted in a synergistic effect in small cell lung carcinoma cell line xenograft models with overexpression of SLFN11 and high MGMT, demonstrating a greater reduced tumor growth compared to treatment with Talzenna (talazoparib) alone (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15359,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Temodar (temozolomide) treatment resulted in reduced tumor growth in small cell lung carcinoma cell line xenograft models with overexpression of SLFN11 and high MGMT, however, to a lesser extent than when compared to the combination of Talzenna (talazoparib) and Temodar (temozolomide) (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1141,
                "therapyName": "Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talzenna (talazoparib) treatment resulted in minimal anti-tumor activity in small cell lung carcinoma cell line xenograft models with decreased expression of SLFN11 and high MGMT when compared to control (PMID: 27708213).",
            "molecularProfile": {
                "id": 30986,
                "profileName": "SLFN11 dec exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15361,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Talzenna (talazoparib) and Temodar (temozolomide) resulted in no greater benefit compared to Talzenna (talazoparib) treatment alone in small cell lung carcinoma cell line xenograft models with decreased expression of SLFN11 and high MGMT (PMID: 27708213).",
            "molecularProfile": {
                "id": 30986,
                "profileName": "SLFN11 dec exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of lung small cell cancer cells harboring KRAS G12V in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16378,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E709_T710delinsD who progressed after a 1 year partial response to Gilotrif (afatinib) was found to have disease that transformed to small cell lung cancer and had acquired a SMAD4 R361C mutation and did not express Tp53 protein (PMID: 30413663).",
            "molecularProfile": {
                "id": 31618,
                "profileName": "EGFR E709_T710delinsD SMAD4 R361C TP53 loss"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14466,
                    "pubMedId": 30413663,
                    "title": "SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30413663"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16445,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (IMpower133) that supported FDA approval, Tecentriq (atezolizumab) in combination with Paraplatin (carboplatin) and Vepesid (etoposide) resulted in significantly improved median overall survival (12.3 vs 10.3 months, HR=0.70, p=0.007) and median progression-free survival (5.2 vs 4.3 months, HR=0.77, p=0.02) compared to placebo in patients with untreated extensive-stage small-cell lung cancer (PMID: 30280641; NCT02763579).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4164,
                "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14518,
                    "pubMedId": 30280641,
                    "title": "First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30280641"
                },
                {
                    "id": 15451,
                    "pubMedId": null,
                    "title": "Tecentriq (atezolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16518,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tecentriq (atezolizumab), Paraplatin (carboplatin), and Vepesid (etoposide) combination treatment is included in guidelines as a preferred first-line systemic therapy for patients with advanced small cell lung cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4164,
                "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16516,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment is included in guidelines for small cell lung cancer patients who have relapsed after primary therapy (NCCN.org).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17353,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (KEYNOTE-158) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 18.7% (20/107) in patients with advanced small-cell lung cancer, with a median progression-free survival of 2.0 months (J Clin Oncol 36, no. 15_suppl (May 20 2018) 8506-8506; NCT02628067).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14400,
                    "pubMedId": null,
                    "title": "Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8506"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16517,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines for small cell lung cancer patients who have relapsed after primary therapy (NCCN.org).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16616,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in a clinical benefit rate of 21.2% (7/33, 1 partial response, 6 stable disease) in patients with NCAM1 (CD56)-positive small cell lung cancer (PMID: 26961907; NCT00346385).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14639,
                    "pubMedId": 26961907,
                    "title": "Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26961907"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16651,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, immune-checkpoint inhibitors (Keytruda (pembrolizumab), n=7; Opdivo (nivolumab), n=24; Opdivo (nivolumab) plus Yervoy (ipilimumab), n=21) resulted in significantly improved median progression-free survival (3.3 vs 1.2 mo, HR=0.37, p<0.01) and median overall survival (10.4 vs 2.5 mo, HR=0.38, p<0.01) in small cell lung cancer patients with high tumor mutational burden (TMB>9.68mut/MB) compared to patients with low TMB (TMB less or equal to 9.68mut/MB) (PMID: 30922388).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14702,
                    "pubMedId": 30922388,
                    "title": "Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30922388"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17231,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, MBG453 and Spartalizumab (PDR001) combination treatment resulted in partial response in a patient with small cell lung cancer (AACR Annual Meeting 2019, Abstract CT183; NCT02608268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8396,
                "therapyName": "MBG453 + Spartalizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15246,
                    "pubMedId": null,
                    "title": "Phase (Ph) I/II study of MBG453\u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer cell lines harboring a CREBBP mutation demonstrated decreased cell viability when treated with Trichostatin A (TSA) in culture (PMID: 31068675).",
            "molecularProfile": {
                "id": 10500,
                "profileName": "CREBBP mutant"
            },
            "therapy": {
                "id": 2867,
                "therapyName": "Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15698,
                    "pubMedId": 31068675,
                    "title": "Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17941,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted in improved progression-free survival (5.7 vs 3.6 months, p=0.009) and overall survival (12.2 vs 7.5 months, p=0.014) in patients with SLFN11-positive (n=12) small cell lung cancer compared to patients with SLFN11-negative (n=14) tumors (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 32904,
                "profileName": "SLFN11 positive"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17942,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted partial response in a patient with small cell lung cancer harboring ATM D2725G, with a progression-free survival of 9 months and an overall survival of 16 months (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 5464,
                "profileName": "ATM D2725G"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17943,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted stable disease in a patient with small cell lung cancer harboring ATM S333F, with a progression-free survival of 4.2 months and an overall survival of 4.2 months (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 27284,
                "profileName": "ATM S333F"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17944,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted stable disease in a patient with small cell lung cancer harboring ATM V410A, with a progression-free survival of 6.3 months and an overall survival of 6.3 months (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 5741,
                "profileName": "ATM V410A"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17945,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted partial response in a patient with small cell lung cancer harboring BRCA2 I1724T, with a progression-free survival of 6.0 months and an overall survival of 10.8 months (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 32907,
                "profileName": "BRCA2 I1724T"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AOH1160 induced DNA damage, cell cycle arrest, and inhibited proliferation of PCNA-positive small cell lung carcinoma cell lines in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 29967249).",
            "molecularProfile": {
                "id": 33953,
                "profileName": "PCNA positive"
            },
            "therapy": {
                "id": 8907,
                "therapyName": "AOH1160",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16726,
                    "pubMedId": 29967249,
                    "title": "The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19377,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Poteligeo (mogamulizumab-kpkc) and Opdivo (nivolumab) combination treatment demonstrated acceptable safety, resulted in an objective response rate of 7% (1/15, 1 partial responses) and a disease control rate of 20% (3/15) in immunotherapy-naive patients with advanced or metastatic small cell lung cancer, response occurred regardless of PD-L1, CCR4, CD8 expression levels and tumor mutational burden (PMID: 31455681; NCT02476123).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3843,
                "therapyName": "Mogamulizumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16935,
                    "pubMedId": 31455681,
                    "title": "A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31455681"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19393,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, combination of Lynparza (olaparib) and Temodar (temozolomide) resulted in an objective response rate of 41.7% (20/48) in patients with relapsed small cell lung cancer, with a median progression-free survival of 4.2 months and a median overall survival of 8.5 months, similar response was recapitulated in a coclinical trial with 32 patient-derived xenograft models (PMID: 31416802; NCT02446704).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1438,
                "therapyName": "Olaparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16946,
                    "pubMedId": 31416802,
                    "title": "Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416802"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20433,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of DT2216 and Venclexta (venetoclax) demonstrated synergy in a small cell lung cancer cell line dependent on BCL-XL and BCL-2 for survival, resulting in decreased cell viability in culture, and led to increased tumor growth inhibition in xenograft models with a mean tumor growth inhibition of 98.2% (PMID: 31792461).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9349,
                "therapyName": "DT2216 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17825,
                    "pubMedId": 31792461,
                    "title": "A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31792461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21213,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (CASPIAN) trial that supported FDA approval, Imfinzi (durvalumab) in combination with Vepesid (etoposide) and Paraplatin (carboplatin) or Platinol (cisplatin) resulted in significantly improved overall survival (13.0 vs 10.3 mo, HR=0.73, p=0.0047) compared to platinum-etoposide therapy in patients with untreated extensive-stage small cell lung cancer (PMID: 31590988; NCT03043872).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9640,
                "therapyName": "Carboplatin + Durvalumab + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18480,
                    "pubMedId": 31590988,
                    "title": "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31590988"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21214,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (CASPIAN) trial that supported FDA approval, Imfinzi (durvalumab) in combination with Vepesid (etoposide) and Paraplatin (carboplatin) or Platinol (cisplatin) resulted in significantly improved overall survival (13.0 vs 10.3 mo, HR=0.73, p=0.0047) compared to platinum-etoposide therapy in patients with untreated extensive-stage small cell lung cancer (PMID: 31590988; NCT03043872).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6904,
                "therapyName": "Cisplatin + Durvalumab + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18480,
                    "pubMedId": 31590988,
                    "title": "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31590988"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00720785",
            "title": "Natural Killer Cells and Bortezomib to Treat Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00926640",
            "title": "A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1123,
                    "therapyName": "Belinostat + Cisplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01286987",
            "title": "Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01306045",
            "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 816,
                    "therapyName": "MK2206",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01450761",
            "title": "Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01579929",
            "title": "Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2504,
                    "therapyName": "Cisplatin + Etoposide + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01587703",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 784,
                    "therapyName": "GSK525762",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01638546",
            "title": "Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01642251",
            "title": "Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01722292",
            "title": "A Study of LY2940680 in Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1587,
                    "therapyName": "Taladegib",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01737502",
            "title": "Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2301,
                    "therapyName": "Auranofin + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01831089",
            "title": "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1196,
                    "therapyName": "Bevacizumab + Lurbinectedin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1197,
                    "therapyName": "Lurbinectedin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01859741",
            "title": "A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 2547,
                    "therapyName": "Tarextumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01892046",
            "title": "Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 866,
                    "therapyName": "SNX-5422",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01928394",
            "title": "Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8260,
                    "therapyName": "Cobimetinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02034123",
            "title": "Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3014,
                    "therapyName": "GSK2879552",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038647",
            "title": "Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02100007",
            "title": "ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2174,
                    "therapyName": "ME-344 + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02152059",
            "title": "A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 831,
                    "therapyName": "Nintedanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02157792",
            "title": "M6620 First in Human Study",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2883,
                    "therapyName": "Irinotecan + VX-970",
                    "synonyms": null
                },
                {
                    "id": 3110,
                    "therapyName": "Cisplatin + Gemcitabine + VX-970",
                    "synonyms": null
                },
                {
                    "id": 8278,
                    "therapyName": "Cisplatin + Etoposide + VX-970",
                    "synonyms": null
                },
                {
                    "id": 3109,
                    "therapyName": "Cisplatin + VX-970",
                    "synonyms": null
                },
                {
                    "id": 8280,
                    "therapyName": "Carboplatin + Cisplatin + VX-970",
                    "synonyms": null
                },
                {
                    "id": 8279,
                    "therapyName": "Gemcitabine + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02161419",
            "title": "RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 663,
                    "therapyName": "Roniciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02200757",
            "title": "Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1440,
                    "therapyName": "Aldoxorubicin",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02247349",
            "title": "BMS-986012 in Relapsed/Refractory SCLC",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4534,
                    "therapyName": "BMS-986012",
                    "synonyms": null
                },
                {
                    "id": 4535,
                    "therapyName": "BMS-986012 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02250885",
            "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02261805",
            "title": "A Phase I/II Study of Ganetespib in Combination With Doxorubicin",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3052,
                    "therapyName": "Aldoxorubicin + Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02289690",
            "title": "Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1544,
                    "therapyName": "Carboplatin + Etoposide + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02331251",
            "title": "Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02351505",
            "title": "Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02359019",
            "title": "Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02402920",
            "title": "Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02419417",
            "title": "Study of BMS-986158 in Subjects With Select Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2811,
                    "therapyName": "BMS986158",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446704",
            "title": "Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454972",
            "title": "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1195,
                    "therapyName": "Lurbinectedin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02472977",
            "title": "Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 2847,
                    "therapyName": "Ulocuplumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02481830",
            "title": "Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2951,
                    "therapyName": "Amrubicin",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02487095",
            "title": "Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2879,
                    "therapyName": "VX-970",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02489903",
            "title": "RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 3680,
                    "therapyName": "RRx-001",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02498613",
            "title": "A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02499770",
            "title": "G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 3074,
                    "therapyName": "Trilaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02514447",
            "title": "Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3074,
                    "therapyName": "Trilaciclib",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02516553",
            "title": "BI 894999 First in Human Dose Finding Study in Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5884,
                    "therapyName": "BI 894999",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02537418",
            "title": "Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02538666",
            "title": "A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02561234",
            "title": "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6634,
                    "therapyName": "Pegzilarginase",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02579226",
            "title": "A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 3547,
                    "therapyName": "AZD2811",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628067",
            "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631733",
            "title": "Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 3314,
                    "therapyName": "Irinotecan + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02649673",
            "title": "LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3845,
                    "therapyName": "LCL161 + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658214",
            "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 8330,
                    "therapyName": "Cisplatin + Durvalumab + Fluorouracil + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8329,
                    "therapyName": "Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8328,
                    "therapyName": "Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8327,
                    "therapyName": "Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8326,
                    "therapyName": "Carboplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8325,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 7524,
                    "therapyName": "Carboplatin + Durvalumab + Gemcitabine + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02660034",
            "title": "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5883,
                    "therapyName": "BGB-A317 + Pamiparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02671955",
            "title": "A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3614,
                    "therapyName": "JNJ-61610588",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02674568",
            "title": "Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3544,
                    "therapyName": "Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02701400",
            "title": "Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3840,
                    "therapyName": "MEDI0562 + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02734004",
            "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 7490,
                    "therapyName": "Bevacizumab + Durvalumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02735980",
            "title": "A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1651,
                    "therapyName": "Prexasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02748889",
            "title": "Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 4164,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02763579",
            "title": "A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4164,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02815592",
            "title": "Trial of BMS-986012 in Combination With Platinum and Etoposide",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 4563,
                    "therapyName": "BMS-986012 + Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 4564,
                    "therapyName": "BMS-986012 + Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02819999",
            "title": "A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4827,
                    "therapyName": "Cisplatin + Etoposide + Rovalpituzumab Tesirine",
                    "synonyms": null
                },
                {
                    "id": 3544,
                    "therapyName": "Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02874664",
            "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3544,
                    "therapyName": "Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02899728",
            "title": "Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4728,
                    "therapyName": "Carboplatin + Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02922764",
            "title": "A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6665,
                    "therapyName": "RGX-104",
                    "synonyms": null
                },
                {
                    "id": 6666,
                    "therapyName": "Nivolumab + RGX-104",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02934503",
            "title": "Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6184,
                    "therapyName": "Carboplatin + Cisplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02936323",
            "title": "PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5819,
                    "therapyName": "PEN-221",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02963090",
            "title": "Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5532,
                    "therapyName": "Pembrolizumab + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03026166",
            "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5640,
                    "therapyName": "Ipilimumab + Nivolumab + Rovalpituzumab Tesirine",
                    "synonyms": null
                },
                {
                    "id": 5641,
                    "therapyName": "Nivolumab + Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03033511",
            "title": "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU)",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5307,
                    "therapyName": "Dexamethasone + Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03041311",
            "title": "Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5541,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide + Trilaciclib",
                    "synonyms": null
                },
                {
                    "id": 4164,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03043599",
            "title": "Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03043872",
            "title": "Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5305,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 5306,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 4728,
                    "therapyName": "Carboplatin + Cisplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03061812",
            "title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3544,
                    "therapyName": "Rovalpituzumab Tesirine",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03066778",
            "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 5145,
                    "therapyName": "Cisplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03076372",
            "title": "A Study Evaluating MM-310 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5758,
                    "therapyName": "MM-310",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03080311",
            "title": "A Study of APG-1252 in Patients With SCLC or Other Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5757,
                    "therapyName": "APG-1252",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03085849",
            "title": "SGI-110 Plus Durvalumab/Tremelimumab in SCLC",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5488,
                    "therapyName": "Durvalumab + Guadecitabine + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03092934",
            "title": "A Study of AK-01 (LY3295668) in Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5753,
                    "therapyName": "LY3295668",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03116971",
            "title": "Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5546,
                    "therapyName": "Cisplatin + Etoposide + MSC2490484A",
                    "synonyms": null
                },
                {
                    "id": 3616,
                    "therapyName": "MSC2490484A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03134638",
            "title": "A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5700,
                    "therapyName": "SY-1365",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03150810",
            "title": "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6124,
                    "therapyName": "Pamiparib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03179436",
            "title": "Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6039,
                    "therapyName": "MK-1308 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03221400",
            "title": "PEN-866 in Patients With Advanced Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4842,
                    "therapyName": "STA-8666",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03313778",
            "title": "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6349,
                    "therapyName": "mRNA-4157 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6348,
                    "therapyName": "mRNA-4157",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319940",
            "title": "Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6407,
                    "therapyName": "AMG 757",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03325816",
            "title": "Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03334487",
            "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 5307,
                    "therapyName": "Dexamethasone + Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361228",
            "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6492,
                    "therapyName": "Epacadostat + INCB001158",
                    "synonyms": null
                },
                {
                    "id": 6493,
                    "therapyName": "Epacadostat + INCB001158 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363893",
            "title": "Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6828,
                    "therapyName": "ICEC0942",
                    "synonyms": null
                },
                {
                    "id": 8454,
                    "therapyName": "Fulvestrant + ICEC0942",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03365791",
            "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03366103",
            "title": "Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6502,
                    "therapyName": "Navitoclax + Vistusertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03371979",
            "title": "Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6635,
                    "therapyName": "Pegzilarginase + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03382561",
            "title": "Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4922,
                    "therapyName": "Cisplatin + Etoposide + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6557,
                    "therapyName": "Carboplatin + Etoposide + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03402880",
            "title": "ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03406715",
            "title": "Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6633,
                    "therapyName": "Ad.p53-DC vaccine + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03460977",
            "title": "PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6785,
                    "therapyName": "PF-06821497",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03509012",
            "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5305,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 6905,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6904,
                    "therapyName": "Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 6903,
                    "therapyName": "Cisplatin + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5306,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517488",
            "title": "A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6973,
                    "therapyName": "XmAb20717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03532880",
            "title": "A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03554473",
            "title": "M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7081,
                    "therapyName": "M7824 + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 7082,
                    "therapyName": "M7824 + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568539",
            "title": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6138,
                    "therapyName": "Sintilimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03575793",
            "title": "A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7156,
                    "therapyName": "Ipilimumab + Nivolumab + Plinabulin",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03639194",
            "title": "A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7323,
                    "therapyName": "ABBV-011 + ABBV-181",
                    "synonyms": null
                },
                {
                    "id": 7322,
                    "therapyName": "ABBV-011",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03662074",
            "title": "Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6297,
                    "therapyName": "Gemcitabine + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03670056",
            "title": "A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03672773",
            "title": "Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1377,
                    "therapyName": "Talazoparib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694249",
            "title": "Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 9193,
                    "therapyName": "Ifetroban sodium",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03703297",
            "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03728361",
            "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3724,
                    "therapyName": "Nivolumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03752398",
            "title": "A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9200,
                    "therapyName": "XmAb23104",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03761914",
            "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6676,
                    "therapyName": "Galinpepimut-S",
                    "synonyms": null
                },
                {
                    "id": 7656,
                    "therapyName": "Galinpepimut-S + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03811002",
            "title": "Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4164,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 8455,
                    "therapyName": "Atezolizumab + Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 2585,
                    "therapyName": "Cisplatin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03811652",
            "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5762,
                    "therapyName": "MEDI7247",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03816345",
            "title": "Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03830918",
            "title": "Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1437,
                    "therapyName": "Niraparib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03849469",
            "title": "A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7902,
                    "therapyName": "Pembrolizumab + XmAb22841",
                    "synonyms": null
                },
                {
                    "id": 7901,
                    "therapyName": "XmAb22841",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03879798",
            "title": "DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8088,
                    "therapyName": "DS-3201b + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03896503",
            "title": "Topotecan With or Without M6620 in Treating Patients With Relapsed Small Cell Lung Cancer or Extrapulmonary Small Cell Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 8917,
                    "therapyName": "Topotecan + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03898791",
            "title": "A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5753,
                    "therapyName": "LY3295668",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03913455",
            "title": "Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8649,
                    "therapyName": "Carboplatin + Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03923270",
            "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03958045",
            "title": "Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6450,
                    "therapyName": "Nivolumab + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03964727",
            "title": "A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03)",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 3227,
                    "therapyName": "Sacituzumab govitecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03977467",
            "title": "Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5983,
                    "therapyName": "Atezolizumab + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 7491,
                    "therapyName": "Atezolizumab + Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 8440,
                    "therapyName": "Atezolizumab + Bevacizumab + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 8439,
                    "therapyName": "Atezolizumab + Bevacizumab + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04010357",
            "title": "Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04032704",
            "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3615,
                    "therapyName": "SGN-LIV1A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04122625",
            "title": "Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9181,
                    "therapyName": "Debio 1143 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134312",
            "title": "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6889,
                    "therapyName": "MVA-BN-Brachyury",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04165330",
            "title": "Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8958,
                    "therapyName": "Anlotinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04170946",
            "title": "Talazoparib and Thoracic RT for ES-SCLC",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04173325",
            "title": "Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 9203,
                    "therapyName": "Irinotecan + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04209595",
            "title": "PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9121,
                    "therapyName": "PLX038 + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04256421",
            "title": "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9317,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide + MTIG7192A",
                    "synonyms": null
                },
                {
                    "id": 4164,
                    "therapyName": "Atezolizumab + Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        }
    ]
}